A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
Status:
Completed
Trial end date:
2016-11-16
Target enrollment:
Participant gender:
Summary
This study is a post-authorization commitment to the European Medicines Agency (EMA). The
study serves to determine whether the treatment of patients with stable, symptomatic Chronic
Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and
safe. The efficacy and safety of the drug was tested for twice daily dosing against once
daily dosing.